These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 26216384

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P.
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, Rini BI.
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [Abstract] [Full Text] [Related]

  • 11. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
    Bjarnason GA, Khalil B, Hudson JM, Williams R, Milot LM, Atri M, Kiss A, Burns PN.
    Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.
    Bjarnason GA, Knox JJ, Kollmannsberger CK, Soulieres D, Ernst DS, Zalewski P, Canil CM, Winquist E, Hotte SJ, North SA, Heng DYC, Macfarlane RJ, Venner PM, Kapoor A, Hansen AR, Eigl BJ, Czaykowski P, Boyd B, Wang L, Basappa NS.
    Eur J Cancer; 2019 Feb; 108():69-77. PubMed ID: 30648632
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
    Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.
    Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.
    Oncology; 2009 Mar; 76(5):350-4. PubMed ID: 19321976
    [Abstract] [Full Text] [Related]

  • 20. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
    Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R.
    Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.